Phreesia, Inc. (PHR)
| Market Cap | 597.30M -56.3% |
| Revenue (ttm) | 480.59M +14.5% |
| Net Income | 2.31M |
| EPS | 0.04 |
| Shares Out | 60.76M |
| PE Ratio | 254.66 |
| Forward PE | 27.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,382,786 |
| Open | 9.59 |
| Previous Close | 9.53 |
| Day's Range | 9.56 - 10.05 |
| 52-Week Range | 7.77 - 32.76 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 21.18 (+115.46%) |
| Earnings Date | May 27, 2026 |
About PHR
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for PHR stock is "Buy." The 12-month stock price target is $21.18, which is an increase of 115.46% from the latest price.
News
Phreesia Sets Release Date for Fiscal First Quarter 2027 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia will release its fiscal first quarter 2027 financial results after the close of market trading on Wednesday, May 27, 2026.
Phreesia Named to Becker's Hospital Review's 2026 List of “Revenue Cycle Management Companies to Know”
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to Becker's Hospital Review's 2026 list of “Revenue Cycle Management...
Phreesia price target lowered to $12 from $15 at KeyBanc
KeyBanc lowered the firm’s price target on Phreesia (PHR) to $12 from $15 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup
MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--MediFind received the DiMe Seal, developed by the Digital Medicine Society, an independent nonprofit advancing the safe use of digital health.
PHR Investors Have Opportunity to Join Phreesia, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phreesia, Inc. (...
Phreesia price target lowered to $15 from $25 at Wells Fargo
Wells Fargo lowered the firm’s price target on Phreesia (PHR) to $15 from $25 and keeps an Overweight rating on the shares. The company’s fiscal 2027 revenue outlook “decelerated sharply,”
Phreesia downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Phreesia (PHR) to Market Perform from Outperform without a price target The company’s updated fiscal 2027 revenue guidance was disappointing, the analyst tells investors in a resea...
Phreesia price target lowered to $20 from $32 at Stephens
Stephens analyst Jeff Garro lowered the firm’s price target on Phreesia (PHR) to $20 from $32 and keeps an Overweight rating on the shares. Shares will be pressured on reduced
Phreesia price target lowered to $14 from $32 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Phreesia (PHR) to $14 from $32 and keeps an Outperform rating on the shares. The company’s Q4 update was
Phreesia price target lowered to $14 from $35 at Needham
Needham lowered the firm’s price target on Phreesia (PHR) to $14 from $35 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for
Phreesia price target lowered to $22 from $32 at Canaccord
Canaccord lowered the firm’s price target on Phreesia (PHR) to $22 from $32 and keeps a Buy rating on the shares. The firm said despite beating 4Q 206 revenue and
Phreesia downgraded to Neutral from Buy at Citi
Citi downgraded Phreesia (PHR) to Neutral from Buy with a price target of $10, down from $25, following the fiscal Q4 report. The company is facing macro pressures which are
Phreesia downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Phreesia (PHR) to Neutral from Overweight with a price target of $16, down from $24. The main takeaway from the Q4 earnings report is the 7% cut to
Phreesia downgraded to Neutral from Outperform at Baird
Baird downgraded Phreesia (PHR) to Neutral from Outperform with a price target of $10, down from $25. The company’s fiscal 2027 revenue outlook was lowered by 7% as its Network
Phreesia downgraded to Hold from Buy at Truist
Truist analyst Jailendra Singh downgraded Phreesia (PHR) to Hold from Buy with a price target of $11, down from $24. The company’s Q4 earnings release came with a “meaningful reduction”
Phreesia Earnings Call Transcript: Q4 2026
Fiscal 2026 saw record Adjusted EBITDA, free cash flow, and first-ever positive GAAP net income, driven by AccessOne and operational efficiency. FY27 revenue guidance was lowered due to pharma spending headwinds, but margin and cash flow outlooks remain strong.
Phreesia cuts FY27 revenue view to $510M-$520M from $545M-$559M
Consensus $552.1M. The company states: ” As we discussed on our last earnings call in December 2025, we are experiencing shorter visibility into spending commitments by certain pharmaceutical manufact...
Phreesia down 21% at $9.00 after Q4 earnings, guidance cut
16:13 EDT Phreesia (PHR) down 21% at $9.00 after Q4 earnings, guidance cut Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
Phreesia reports Q4 adjusted EBITDA $29.4M vs. $16.4M last year
Reports Q4 revenue $127.1M, consensus $126.6M. “We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossin...
Phreesia Announces Fourth Quarter Fiscal 2026 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended Jan...
Phreesia price target lowered to $25 from $30 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Phreesia (PHR) to $25 from $30 and keeps an Overweight rating on the shares. The firm says network momentum,
Phreesia Named One of Becker's Top Places to Work in Healthcare
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named one of Becker's Healthcare's Top Places to Work in Healthcare for 20...
Phreesia price target lowered to $19 from $22 at Mizuho
Mizuho analyst Steven Valiquette lowered the firm’s price target on Phreesia (PHR) to $19 from $22 and keeps an Outperform rating on the shares ahead of the fiscal Q4 report
Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia and Sesame Workshop received the Point of Care Excellence Award for their pediatric health and wellness campaign.